|
|
|
|
|
|
|
M T W Th Fri |
|
28 August, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
BioNTech and Genentech terminated a Phase 2 trial of their personalized mRNA cancer vaccine in certain colorectal cancer patients. The failure in that 'cold' tumor, as Kyle LaHucik explains, comes only a week after Moderna and Merck’s success in a 'hot' tumor with their own cancer vaccine for the more-immune-vulnerable melanoma. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Kyle LaHucik
|
BioNTech has axed a Phase 2 trial of its personalized mRNA cancer vaccine just a week after Moderna and Merck had breakout success for their... | |
|
|
|
|
|
|
by Ayisha Sharma
|
DualityBio saidFriday it will receive $45 million upfront from Roche’s Genentech to develop drugs that could be part of a new wave of antibody-drug... | |
|
|
|
 |
|
ESC Congress in Munich (Elizabeth Cairns for Endpoints News) |
|
|
|
by Elizabeth Cairns
|
MUNICH— The surprise failure of a high-profile study of AstraZeneca and Ionis Pharmaceuticals’ Wainua can be attributed to patients in the trial also taking... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus news about AusperBio and Samsung Biologics. Eli Lilly’s Mounjaro wins heart approval: The blockbuster drug, whose generic name is tirzepatide, was approved on Friday... | |
|
|
|
|
|
|
|
|
by Max Bayer
|
The FDA approved Roivant’s dermatomyositis drug brepocitinib on Thursday, the first major regulatory nod that could usher in a multibillion-dollar revenue stream for the hub-and-spoke... | |
|
|
|
|
|
